Antiplatelet drugs and gastrointestinal disorders: when and how effective are inhibitors of proton pump?
Terapevticheskii arkhiv 83(10): 68-71
2011
ISSN/ISBN: 0040-3660 PMID: 22185030 Document Number: 652601
Antiplatelet drugs are essential in current treatment of coronary heart disease (CHD) but they have an adverse action--damage to gastrointestinal mucosa. Long-term administration of several medicines in CHD patients makes possible interaction of some drugs. Clinical trials show that proton pump inhibitors (PPI) reduce frequency of recurrent gastrointestinal bleedings in patients of high cardiological risk on antiplatelet therapy. In prescription of PPI to CHD patients at high risk of gastropathy, it is necessary to consider both efficacy and safety of the drug.